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Background: The purpose of this review was to provide a critical appraisal of the literature 
supporting the efficacy of ophthalmic ketorolac (Acuvail®) in the treatment of pain and inflam-
mation after cataract surgery.
Methods: Literature search and expert opinion of the authors.
Results: Recent studies indicate greater intraocular drug levels in the anterior chamber and 
iris-ciliary body after topical application of Acuvail in comparison with older formulations of 
ketorolac. A large randomized, multicenter, placebo-controlled study demonstrated significantly 
less inflammation and pain after cataract surgery using Acuvail.
Conclusion: Acuvail appears to be effective in reducing post-cataract surgery pain and 
inflammation.
Keywords: ketorolac tromethamine, Acuvail®, postsurgical, cystoid macular edema, nonsteroi-
dal anti-inflammatory drugs
Introduction
Inflammation frequently complicates intraocular surgery and can result in pain, elevated 
intraocular pressure, and cystoid macular edema (CME).1–3 CME is the most common 
cause of vision loss after uncomplicated cataract surgery and although its pathogen-
esis remains incompletely understood, inflammation is a known cause.4 Excessive 
or persistent postoperative inflammation may also lead to prolonged compromise of 
the blood–ocular barrier and may increase the risk of chronic inflammation. Topical 
corticosteroids are effective for reducing and treating inflammation in the setting of 
cataract surgery, and have a long track record of ophthalmic use, but are limited by side 
effects, including elevated intraocular pressure, delayed wound healing, and increase 
risk of infection. Consequently, safer alternative anti-inflammatory agents to prevent 
and treat excessive postoperative inflammation and pain following cataract surgery 
would be advantageous.
Cyclo-oxygenase (COX) is an important enzyme in the inflammatory process and 
catalyzes the biosynthesis of prostaglandins and thromboxanes from arachidonic acid.1 
Two main isoforms, COX-1 and COX-2, have been well characterized. COX-1 is con-
stitutively expressed in most mammalian cells, including the kidney, gastrointestinal 
tract, platelets, and vascular endothelium, and plays a pivotal role in normal physi-
ological function. COX-2, on the other hand, is an inducible enzyme that is thought 
to be primarily responsible for inflammatory-mediated reactions.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are potent inhibitors of COX 
enzymes and thereby the synthesis of prostaglandins. While the anti-inflammatory Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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actions of corticosteroids are in part from the inhibition of 
phospholipase A2 preventing the release of arachidonic acid 
from membrane-bound phospholipids, NSAIDs act more 
downstream in the cascade and directly inhibit COX-1 and 
COX-2 enzymes. Within the eye, it is firmly established that 
prostaglandins disrupt the blood–ocular barrier, increase 
vasodilation, facilitate leukocyte migration, and promote 
pain.1 Consequently, their inhibition should have favorable 
effects on both intraocular inflammation and pain.
In support of this, several randomized, prospective, 
double-masked, and placebo-controlled studies have shown 
that topically applied indomethacin 1%, flurbiprofen 0.03%, 
ketorolac 0.4% and 0.5%, diclofenac 0.1%, nepafenac 0.1%, 
and bromfenac 0.09% reduce postoperative inflammation fol-
lowing cataract surgery.1 Similarly, prospective randomized 
studies have demonstrated that diclofenac 0.1%, ketorolac 
0.4%, nepafenac 0.1%, and bromfenac 0.09% reduce ocular 
discomfort after cataract surgery.1
Of all the commercially available ophthalmic NSAIDs, 
ketorolac tromethamine (ketorolac) possesses the greatest 
number of studies supporting its efficacy in preventing 
and treating postoperative inflammation and pain after 
cataract surgery (Table 1).5–21 Ketorolac 0.5% (Acular®, 
Allergan Inc, Irvine, CA) is approved by the Food and Drug 
administration (FDA) for seasonal allergic conjunctivitis, 
inflammation following cataract surgery, and ocular dis-
comfort after refractive surgery.22 To reduce the incidence 
of burning and stinging, a 0.4% concentration of ketorolac 
(Acular LS®, Allergan Inc) was formulated, and appears 
to have a similar therapeutic effect.18,23 Ketorolac 0.4% is 
approved by the FDA for the reduction of ocular pain and 
burning following corneal refractive surgery. Both the 
0.5% and 0.4% preparations are dosed four times daily. 
More recently, a preservative-free 0.45% preparation of 
ketorolac (Acuvail®, Allergan Inc) in carboxymethylcel-
lulose was approved by the FDA in 2009 for the treatment 
of pain and inflammation following cataract surgery and 
is dosed twice daily.24 The specific intent of this review 
is to assess the available evidence supporting the efficacy 
of Acuvail in the treatment of pain and inflammation after 
cataract surgery.
Pharmacology of ketorolac
NSAIDs are a chemically heterogenous group of compounds 
that inhibit the formation of prostaglandins and lack a steroid 
nucleus biosynthetically derived from cholesterol. There are 
six major classes, but topical formulations are limited to the 
relatively water-soluble classes, ie, indole acetic, aryl acetic, 
and aryl propionic acids.25
Ketorolac tromethamine is an aryl acetic acid   derivative. 
The chemical name is (±)-5-benzoyl-2,3- dihydro-1H-
  pyrrolizine-1-carboxylic acid, compounded with 2-amino-
2-(hydroxymethyl)-1,3-propanediol (1:1). The molecular 
weight is 376.41 and the molecular formula is C19H24N2O6. 
Current preparations consist of a racemic mixture of R-(+) 
and S-(-) ketorolac tromethamine.
When administered systemically, ketorolac has proven 
analgesic, anti-inflammatory, and antipyretic activity.1 Its 
mechanism of action, as with all NSAIDs, is presumed to 
be due to inhibition of prostaglandin biosynthesis. However, 
systemic administration is not thought to achieve sufficient 
intraocular drug levels to inhibit prostaglandin synthesis 
completely in the ciliary body and iris.1 Topical administra-
tion of ketorolac, on the other hand, reaches adequate levels 
to inhibit prostaglandin synthesis in these target tissues. In 
one study, after a single topical application of ketorolac 0.4%, 
a peak aqueous concentration of 57.5 ng/mL was achieved 
after 60 minutes.26 Another study demonstrated mean aque-
ous concentration of 1079 ng/mL after a total of 12 doses of 
ketorolac 0.4% administered over 2 days.27
The original ophthalmic formulation of ketorolac is a 
0.5% solution marketed as Acular. A 0.4% formulation 
(Acular LS) was introduced in the US in 2003. The 0.5% 
and 0.4% preparations are supplied as an isotonic aqueous 
mixture with a pH of 7.4, and have an osmolality of approxi-
mately 290 mOsmol/kg. However, both the 0.4% and 0.5% 
solutions contain benzalkonium chloride (a preservative), 
the surfactant octoxynol-40, and sodium edetate (a metal-
chelating agent), and are associated with a high incidence of 
burning and stinging on instillation (as high as 40%).22,23,28
In an effort to increase ocular bioavailability, a new 
formulation of ketorolac was developed to preserve the 
efficacy of prior formulations, while enhancing tolerability 
with a less frequent dosing regimen.21 Compared with the 
ketorolac 0.4% formulation, the concentration of Acuvail 
is 12% greater (0.45%) and carboxymethylcellulose is 
added to the emulsion to allow greater drug retention on 
the ocular surface and improve comfort and drug penetra-
tion. Other key changes include lower pH and absence of 
surfactant, metal-chelating agents, and preservatives. As 
such, Acuvail is supplied as a sterile isotonic preservative-
free solution with a pH and osmolality of approximately 
6.8 and 285 mOsmol/kg, respectively, and is approved by 
the FDA for treatment of pain and inflammation following 
cataract surgery.
In a study by Attar et al evaluating the pharmacokinetics of 
ketorolac 0.45% versus 0.4%, the addition of carboxymethylcel-
lulose in combination with the 12% increase in concentration Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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resulted in a 35% enhancement of bioavailability in the aqueous 
humor of the 0.45% preparation.29 Furthermore, decreas-
ing the pH from 7.4 to 6.8 in combination with addition of 
carboxymethylcellulose enhanced bioavailability in the aqueous 
humor by two-fold and in the iris-ciliary body by three-fold.
At the time of writing, the pharmacokinetics of Acuvail 
have not been assessed in humans, but both Acular LS and 
Acuvail formulations were directly compared after a single 
topical application of 35 µL.29 Peak concentration in the aque-
ous humor and iris-ciliary body was 389 ng/mL and 450 ng/g, 
Table 1 Clinical studies with ketorolac in post-cataract surgery inflammation and pain
Author Year Patients/Eyes Ketorolac Dosing regimen P = cells/flare P = pain Conclusions
el Harazi et al5 1988 58 pts 0.50% 4 × daily 1 wk then  
BiD × 3 wks
Ketorolac =  
diclofenac =  
prednisolone 1% for  
inflammation
Flach et al6 1988 118 pts 0.50% 1 gtt 3 × daily 0.001 Ketorolac . placebo   
for inflammation
Flach et al7 1989 127 pts 0.50% Pre and  
postoperatively
0.53 Ketorolac =  
dexamethasone for  
inflammation
Ostrov et al8 1997 157 pts 0.50% 1 day preop and  
4 wks postop
Ketorolac =  
prednisone 1% =  
dexamethasone for  
inflammation
Heier et al9 1999 102 pts 0.50% 4 × daily 0.030/0.025 0.049 Ketorolac . placebo   
for inflammation and  
pain
Simone et al10 1999 59 pts 0.50% 1 to 2 drops  
4 times daily ×  
1 wk then tapered
Ketorolac = 
prednisolone 1% for 
inflammation and pain
Snyder et al11 2000 26 pts 0.50% Pre and  
postoperatively
Ketorolac =  
flurbiprofen/ 
prednisolone 1% for  
inflammation
Soloman et al12 2001 104 eyes 0.50% 4 × daily starting  
24 hrs after surgery
0.0002/0.001 0.043 Ketorolac . placebo   
for inflammation
Soloman et al13 2001 36 pts 0.50% 4 × daily starting  
24 hrs after surgery
0.17/0.48 Ketorolac =  
rimexolone 1% for  
cell/flare
Holzer et al14 2002 60 pts 0.50% 4 times a day × 1 wk  
then BiD × 3 wks
Ketorolac =  
loteprednol for  
inflammation
Trinivarat et al15 2003 120 pts 0.50% 4 × daily 0.008 Prednisolone .  
ketorolac for  
inflammation
Price and Price16 2004 25 pts (50 eyes) 0.40% 4 × daily starting  
3 days prior and  
1 day after Ce
0.02 Ketorolac . placebo   
for pain
Donnenfeld et al17 2006 4 grps of 25 0.40% 4 times daily  
pre and post  
operatively
0.001 0.001 Preoperative  
ketorolac decreased  
inflammation
Sandoval et al18 2006 40 eyes total 0.4%/0.5% 4 × daily × 1 wk  
then BiD × 3 wks
Comparative study  
revealed 0.5% .  
stinging/burning
Duong et al19 2007 193 eyes 0.40% 4 × daily 0.33 0.025 Ketorolac .  
nepafenac for pain
Maca et al20 2010 100 pts 0.50% 4 × daily 0.001 Diclofenac =  
ketorolac for  
inflammation
Donnenfeld et al21 2011 511 pts 0.45% 2 × daily 0.001 0.001 Ketorolac .  
placebo for pain and  
inflammationClinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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respectively, for Acuvail, and 211 ng/mL and 216 ng/g, 
respectively, for Acular LS. This study concluded that Acuvail 
delivered significantly higher concentrations of ketorolac 
to the aqueous humor and iris-ciliary body. Waterbury et al 
directly compared the peak and trough intraocular levels of 
Acuvail, bromfenac 0.9% (Xibrom®, ISTA Pharmaceuticals 
Inc, Irvine, CA), and placebo after three applications (35 µL) 
every 20 minutes in an animal model of lipopolysaccharide-
induced inflammation.30 Peak concentrations in the aqueous 
humor and iris-ciliary body were 738 ng/mL and 556 ng/g, 
respectively, for Acuvail and 94 ng/mL and 46 ng/g, respec-
tively, for bromfenac 0.9%. Trough concentrations in the 
aqueous humor and iris-ciliary body were 127 ng/mL and 
59 ng/g, respectively, for Acuvail, and 17 ng/mL and 8 ng/g, 
respectively, for bromfenac 0.9%. The study concluded that 
Acuvail achieved aqueous and iris-ciliary body concentrations 
that exceeded its inhibitory concentration of 50% (IC50) values 
for COX-1 and COX-2 at both peak and trough (Table 2).1,26,31,32 
In addition, while both NSAIDs inhibited lipopolysaccharide-
induced aqueous prostaglandin E2 elevation, only Acuvail 
significantly prevented vascular leakage, as measured by 
fluorescein isothiocyanate-dextran leakage at trough levels.
 Although suggestive, the number of animals used in 
both studies was small, and therefore additional studies 
with larger sample sizes are needed to confirm these initial 
results. Furthermore, both studies used New Zealand white 
rabbits which lack pigment, blink infrequently, and have an 
unusually unstable blood–aqueous barrier, so these results 
should be extrapolated to humans with caution.
Given the favorable pharmacokinetic data of Acuvail, 
approval was granted for twice-daily dosing in contrast with four 
times daily dosing for Acular LS. This reduced dosing regimen 
offers a distinct therapeutic advantage for Acuvail because in 
addition to patient convenience, several studies have suggested 
increased patient compliance with less frequent dosing.33
Efficacy studies
The efficacy of Acuvail was assessed in two identical mul-
ticenter, double-masked, randomized, placebo-controlled, 
parallel studies and specifically conducted to evaluate the 
effects of Acuvail on relief of pain and inflammation after 
cataract surgery.21 The results of these parallel studies were 
analyzed together and collectively involved 511 patients.
Patients were randomized in a 2:1 ratio to receive either 
Acuvail or vehicle in the operative eye for 16 days. Patients 
were dosed twice daily the day before surgery. On the day of 
surgery, patients had one drop upon awakening, three drops 
each 20 minutes apart starting two hours before surgery, one 
drop before discharge, and one drop 12 hours after the first dose 
upon awakening, resulting in a total of six drops of the study 
medication. Patients continued one drop twice daily of the 
study medication for 14 days after surgery. No patients were 
exposed to topical corticosteroids during the study period.
All patients underwent elective unilateral, uncomplicated, 
extracapsular cataract extraction with posterior chamber 
intraocular lens implantation. Patients were evaluated on 
postoperative days 1, 3, 7, and 14. The primary efficacy end-
point was the percentage of patients with a summed ocular 
inflammation score (SOIS) of 0 for anterior chamber cell 
and flare on day 14. The main secondary efficacy endpoint 
was the percentage of patients with no pain (grade = 0) on 
postoperative day 1.
In this study, anterior chamber cell was graded on a 
six-point scale and anterior chamber flare was graded on 
a five-point scale. The SOIS was calculated as the sum of 
scores for anterior chamber cell and flare. To assess the 
degree of pain, patients called an interactive voice response 
system diary twice daily during the two weeks after the day 
of surgery and were instructed to rate their level of ocular 
pain on a five-point scale (0 = none, 1 = mild, 2 = moderate, 
3 = severe, 4 = intolerable).
The Acuvail group had a significantly higher percentage 
of patients with a SOIS score of 0 compared with vehicle 
at days 7 and 14. At day 7, Acuvail and vehicle had a SOIS 
score of 0 for 32% (102/318) and 17% (26/155) of patients, 
respectively (P , 0.001). At day 14, Acuvail and vehicle 
had a SOIS score of 0 for 53% (167/318) and 27% (41/155) 
of patients, respectively (P , 0.001).
Acuvail was also significantly superior to vehicle in 
resolving ocular pain after cataract surgery. A pain score of 
0 on day 1 was reported in 72% (233/322) of Acuvail patients 
versus 40% (62/156) in vehicle patients (P , 0.001). The 
median time to postoperative ocular pain resolution was one 
day in patients treated with Acuvail and two days in patients 
treated with vehicle (P , 0.001).
Although the combined results of these controlled studies 
demonstrate the efficacy of Acuvail for the prevention and 
Table 2 Reported ranges of iC50 for COX-1 and COX-2 of 
ocular NSAiDs
Drug COX-1 IC50 μm (ng/mL) COX-2 IC50 μm (ng/mL)
Amfenac 0.14 to 0.25 (35.6 to 63.6) 0.002 to 0.15 (0.51 to 38.1)
Diclofenac 0.12 to 0.95 (38 to 302.1) 0.03 to 0.09 (9.5 to 28.6)
Ketorolac 0.014 to 0.02 (5.3 to 7.5) 0.09 to 0.12 (33.9 to 45.2)
Bromfenac 0.09 to 0.53 (3.4 to 203.1) 0.007 to 0.023 (2.7 to 8.8)
Abbreviations: COX, cyclooxygenase; iC50, half-maximum inhibition relative to 
control values.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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treatment of postoperative inflammation and pain after 
cataract surgery, these results should be interpreted with 
caution. The importance of achieving a median of one less 
day of pain with Acuvail versus placebo needs to be assessed 
in the appropriate context of treatment cost, clinical impact, 
and in the absence of concomitant corticosteroid use. More-
over, cell and flare were combined together in contrast with 
grading each outcome independently, and their summation 
may have amplified the treatment differences observed 
between the Acuvail and vehicle group. In addition, because 
corticosteroids were not used concomitantly, no information 
can be discerned about the additive benefits of Acuvail with 
a corticosteroid in regards to inflammation and pain follow-
ing cataract surgery. In a study comparing the efficacy of 
ketorolac 0.5% with prednisolone acetate 1%, Simone et al 
observed that prednisolone acetate was more effective at 
reducing intraocular inflammation by day 7 after cataract sur-
gery than ketorolac, although this difference resolved by day 
28.10 Several studies have demonstrated an additive benefit 
of a topical NSAID with a corticosteroid and their combined 
use, therefore, is common in clinical practice.1 Therefore, the 
results of this study cannot be directly applied in the setting 
of concomitant corticosteroid use. Nevertheless, previous 
studies have demonstrated an additive benefit of ketorolac 
0.5% or 0.4% when used in conjunction with corticosteroids 
in reducing inflammation, pain, and CME following cata-
ract surgery. Thus, given the favorable pharmacokinetics of 
Acuvail in comparison with these older formulations, similar 
therapeutic benefit may be likely.5–21
Selective COX-1 versus 
COX-2 inhibition
Several in vitro studies indicate that ketorolac is the most 
potent inhibitor of COX-1, while both amfenac (active com-
ponent in Nevanac®, Alcon Laboratories Inc, Fort Worth, TX) 
and bromfenac have been reported as being the most potent 
inhibitors of COX-2.1,26,31,32 Bromfenac may be a 3–18 times 
more potent inhibitor of COX-2 than diclofenac, amfenac, 
and ketorolac.25,32 Another study found that amfenac was a 
more potent inhibitor of COX-2 than bromfenac.   Differences 
in experimental testing and design may explain these conflict-
ing findings. COX-2 is an inducible enzyme and is thought 
to be primarily responsible for inflammation. Therefore, the 
anti-inflammatory actions of NSAIDs are presumed to relate 
to their ability to inhibit this isoform. However, this paradigm 
has not been consistently demonstrated in clinical trials, and 
the possibility exists that COX-1 also plays an important role 
in inflammation and, in the presence of substrate, may readily 
convert arachidonic acids into prostaglandins. Thus, the 
clinical importance of selective COX-1 versus COX-2 inhibi-
tion for ocular disease remains unproven.
Although ketorolac is approximately six times more 
potent as an inhibitor of COX-1 than COX-2 (Table 2), it is 
nevertheless a potent inhibitor of COX-2, with an IC50 in the 
range of 0.09–0.12 µM (33.9–45.2 ng/mL).32 This allows ketor-
olac to inhibit COX-2 in the iris-ciliary body after topical appli-
cation, an important fact that can be overlooked if the relative 
COX-1/COX-2 potencies of ocular NSAIDs are emphasized. 
On the other hand, ketorolac is an approximately 5–50 times 
more potent inhibitor of COX-1 than diclofenac, bromfenac, 
and amfenac. The ability to inhibit both isoforms of COX for 
short periods of time may be advantageous in allowing more 
rapid and complete inhibition of prostaglandin production, but 
long-term inhibition of COX-1 may not be desirable because 
it is involved in normal physiologic function.
NSAIDs and corticosteroids
The combination use of topical NSAIDs and corticosteroids 
is sometimes referred to as “synergistic” in the literature. This 
clinical impression of synergy remains unproven and would 
seem unlikely, given the fact that both drug classes inhibit 
prostaglandin production (Figure 1). Synergy is defined, in 
general, as two or more agents working in combination to 
produce an effect that could not be obtained by each agent 
independently. A classic example of synergy involves penicil-
lin and aminoglycoside antibiotics where use of both anti-
biotics in combination significantly lowers the IC50 of each 
antibiotic for a given organism. Although a large, randomized, 
prospective study demonstrated that ketorolac 0.5% was 
more effective than dexamethasone sodium phosphate 0.1% 
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solution in facilitating re-establishment of the blood–aqueous 
barrier after surgery, differences in drug formulation and 
intraocular concentration preclude any conclusions about 
synergy.34–36 Furthermore, although many prospective stud-
ies have confirmed that the combination use of an NSAID 
and corticosteroid is superior to a corticosteroid alone for 
pain, inflammation, CME, and visual improvement after 
intraocular surgery, these findings can be explained by an 
additive effect of a second anti-inflammatory agent.1,17,37 The 
distinction between a synergistic effect and an additive effect 
has important implications because synergy implies that an 
NSAID used in combination with a corticosteroid provides a 
therapeutic effect that cannot be replicated by simply increas-
ing the dosing regimen of the corticosteroid.
Ketorolac and posterior segment 
disease
Although topical administration of NSAIDs provides 
aqueous humor levels adequate to suppress prostaglandin 
synthesis in the iris and ciliary body, the ability to suppress 
prostaglandin synthesis in the retina/choroid is less certain. 
In an animal model, ketorolac 0.5% could not be detected 
in the vitreous after topical administration, but in a small 
prospective comparative study of patients undergoing vit-
rectomy, ketorolac 0.4% could be detected in the vitreous 
(2.8 ng/mL) and reduced vitreous prostaglandin E2 levels.38,39 
This observed reduction was presumably from inhibition of 
iris and ciliary body prostaglandin E2 production because the 
measured vitreous concentration of ketorolac was consider-
ably less than the IC50 for both COX-1 and COX-2 inhibi-
tion, and therefore unlikely to have inhibited COX activity 
in retinal cells.
Accumulating evidence indicates that COX-2 has impor-
tant implications for retinal disease.1,40 COX-2 is the predomi-
nant isoform in human retinal pigment epithelial cells and 
is significantly upregulated in response to proinflammatory 
cytokines.41 COX-2 is also present in choroidal neovascular-
ization, as well as in other highly vascularized lesions, and its 
expression increases in diabetic retinopathy.1,42 In a variety of 
experimental systems, COX-2 inhibition suppresses angio-
genesis.43 In this regard, both nepafenac 0.1% and bromfenac 
0.09% could be detected in the rabbit retina after topical 
administration, and in one study nepafenac inhibited 55% of 
retinal prostaglandin synthesis.31,44 In another study, topical 
ketorolac 0.4% inhibited experimentally induced choroidal 
neovascularization and reduced both retinal prostaglandin E2 
and vascular endothelial growth factor levels by .30%.45 
While interesting, these results were obtained in animal 
  models and cannot be directly extrapolated to humans. Given 
the favorable pharmacokinetics of Acuvail versus Acular LS, 
it is worth speculating that clinically meaningful retinal COX 
inhibition may now be achievable.
Safety and tolerability
The overall incidence of treatment-related adverse events 
was significantly higher in the vehicle group (14%) than in 
the Acuvail group (6%).21 The most common adverse events 
reported were increased intraocular pressure, conjunctival 
hyperemia, and/or hemorrhage, corneal edema, ocular pain, 
headache, tearing, and blurred vision. The most common 
adverse events reported at a higher frequency than vehicle 
included increased intraocular pressure (5.8% versus 1.8%), 
conjunctival hemorrhage (1.2% versus 0.6%), and blurred 
vision (1.2% versus 0.6%), and were generally considered by 
the clinical investigators to be a consequence of the cataract 
procedure. Adverse events of burning and stinging were low, 
with only 1.5% of patents in the Acuvail group and 0.6% in 
the vehicle group reporting such an occurrence.
When ketorolac 0.5% was topically applied in one eye 
three times daily, only five of 26 subjects had a detectable 
amount of ketorolac in their plasma (range 10.7–22.5 ng/mL) 
at day 10. In contrast, when ketorolac 10 mg was administered 
systemically every six hours, peak plasma levels were around 
960 ng/mL. Given the possibility of systemic absorption 
after topical application, techniques such as lid closure and 
nasolacrimal occlusion may be used to decrease systemic 
exposure.
As with other NSAIDs, Acuvail may slow or delay 
healing, and in some susceptible patients, continued use of 
topical NSAIDs may result in epithelial breakdown, corneal 
thinning, corneal erosion, corneal ulceration, or corneal 
perforation. There exists the potential for cross-sensitivity 
to acetylsalicylic acid, phenylacetic acid derivatives, and 
other NSAIDs, and therefore caution should be used when 
treating individuals who have previously exhibited sensi-
tivities to these drugs. NSAIDs interfere with thrombocyte 
aggregation and may prolong bleeding time. Therefore, it is 
recommended that topical NSAIDs be used with caution in 
patients with known bleeding tendencies or who are receiv-
ing anticoagulation.
There are no adequate well controlled studies of topical 
NSAIDs in pregnant woman and, as such, these medications 
are classified as Category C. Because of the known effects 
of prostaglandin-inhibiting drugs on the fetal cardiovascular 
system (closure of the ductus arteriosus), the use of topical 
NSAIDs should be avoided during late pregnancy.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Severe corneal toxicity has been reported with diclofenac 
0.1%, ketorolac 0.5%, nepafenac 0.1%, and bromfenac 
0.09%.1 Although uncommon, these dramatic events are 
referred to as corneal melt. However, a definite link between 
NSAID use and corneal melt remains unproven, but it is still 
prudent to avoid NSAID use in patients with severe corneal 
surface disease.
Patient satisfaction
There are limited data on patient satisfaction with Acuvail. 
Older formulations of ketorolac had an incidence of tran-
sient burning and stinging on instillation of approximately 
20%–40% for the 0.4% concentration and 40% for the 0.5% 
concentration.22,23 In contrast, Acuvail was associated with 
substantially lower rates (1.5%) of burning and stinging.21
Most importantly, a significantly higher percentage 
of patients randomized to Acuvail had a 3-line or more 
improvement in vision from baseline compared with those 
treated with vehicle.21 At least two previously published 
studies using ketorolac 0.4% demonstrated a similar ben-
eficial effect upon visual acuity following cataract and 
vitreoretinal surgery.17,37 In patients undergoing routine   
vitreoretinal surgery, patients randomized to ketorolac 0.4% 
experienced an average 4.3-line improvement from baseline 
compared with a 2.5-line improvement with placebo.37 This 
greater improvement in vision in the ketorolac group was 
observed despite concomitant corticosteroid use in both 
groups.
Conclusion
Excessive postoperative inflammation and pain after 
cataract surgery can delay visual recovery and affect 
long-term outcomes. There is substantial evidence from 
well designed studies with sufficient numbers of patients 
that ketorolac formulations 0.4% and 0.5% effectively 
treat both inflammation and pain after cataract surgery. 
Recent evidence indicates that Acuvail possesses similar 
therapeutic benefit. Given the favorable pharmacokinet-
ics, better tolerance, and reduced dosing requirement of 
Acuvail, additional clinical studies comparing Acuvail 
with other NSAIDs for the treatment of inflammation and 
pain after cataract surgery are indicated to confirm these 
promising results.
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